WEC
RARE icon

Winslow Evans & Crocker’s Ultragenyx Pharmaceutical RARE Stock Holding History

Winslow Evans & Crocker’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$16K Hold
112
– – ﹤0.01% 850
2020
Q3 		$9K Hold
112
– – ﹤0.01% 780
2020
Q2 		$9K Hold
112
– – ﹤0.01% 766
2020
Q1 		$6K Hold
112
– – ﹤0.01% 832
2019
Q4 		$6K Hold
112
– – ﹤0.01% 949
2019
Q3 		$6K Buy
+112
New +$6.08K ﹤0.01% 933

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Winslow Evans & Crocker's RARE Position: Q4 2020 in Review

Winslow Evans & Crocker held its Ultragenyx Pharmaceutical (RARE) position steady in Q4 2020 at 112 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Winslow Evans & Crocker first reported a position in RARE in Q3 2019 and has held it in 6 quarters since. 252 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

  • Winslow Evans & Crocker held 112 shares of Ultragenyx Pharmaceutical worth $16K as of Q4 2020.
  • Winslow Evans & Crocker left its Ultragenyx Pharmaceutical share count unchanged in Q4 2020.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #850 holding.
  • Winslow Evans & Crocker first reported a position in Ultragenyx Pharmaceutical in Q3 2019 and has held it in 6 quarters since.
  • 252 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.